Register Login
Register to leave comments
  • News bot Jan. 7, 2026, 10:14 p.m.

    📋 JASPER THERAPEUTICS, INC. (JSPRW) - Clinical Trial Update

    Filing Date: 2026-01-07

    Accepted: 2026-01-07 16:35:06

    Event Type: Clinical Trial Update

    Event Details:

    Jasper Therapeutics Inc. (JSPRW) Announces Clinical Trial Update Jasper Therapeutics Inc. (JSPRW) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: study, program
    • Diseases/Conditions: briquilimab in CSU
    • Clinical Stage: clinical trial
    • Collaboration: Board of Directors
      • targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, announced that its Board of Directors has appointed Jeet Mahal as Chief Executive Officer and a member of the Board, effective January 5, 2026

    🔬 Clinical Development Pipeline (JASPER THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Briquilimab DRUG Phase PHASE1 Chronic Inducible Urticaria ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Jasper Therapeutics Inc.
    • CIK: 0001788028
    • Ticker Symbol: JSPRW
    • Period End Date: 2026-01-02
    • Document Type: 8-K

Search

News categories